Get the Stockscreener App
25.75
2.16%
0.545
Newamsterdam Pharma Company N V stock is traded at $25.75, with a volume of 307.
It is up +2.16% in the last 24 hours and down -4.61% over the past month.
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral and non-statin medicines for patients at high risk of cardiovascular disease. Its lead product candidate is obicetrapib, a next generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in four ongoing Phase 3 and Phase 2b clinical trials as both a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events (MACE). NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
See More
Previous Close:
$25.20
Open:
$23.8
24h Volume:
307
Relative Volume:
0.06
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-13.32%
1M Performance:
-4.61%
6M Performance:
+168.74%
1Y Performance:
+247.44%
1-Day Range:
$23.80
$25.75
1-Week Range:
$23.80
$27.74
52-Week Range:
$5.45
$29.99
Newamsterdam Pharma Company N V Stock (NAMSW) Company Profile
Name
Newamsterdam Pharma Company N V
Sector
Industry
Phone
31 35 206 2971
Address
Gooimeer 2-35, Naarden
Compare NAMSW with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NAMSW
Newamsterdam Pharma Company N V
|
25.75 | 0 | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.48 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.36 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.12 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
901.17 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.00 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Newamsterdam Pharma Company N V Stock (NAMSW) Latest News
NewAmsterdam Pharma Company N.V. $NAMS Shares Sold by Affinity Asset Advisors LLC - MarketBeat
NewAmsterdam Pharma Company Grants Inducement Share Options to New Hires - Quiver Quantitative
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Saturn V Capital Management LP Buys 104,342 Shares of NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
Will NewAmsterdam Pharma Company N.V. Equity Warrant stock gain from lower inflationMarket Growth Review & Free Technical Pattern Based Buy Signals - Newser
Is NewAmsterdam Pharma Company N.V. (KH6) stock attractive post correction2025 Volatility Report & Weekly High Conviction Trade Ideas - Newser
Will NewAmsterdam Pharma Company N.V. Equity Warrant stock see PE expansionJuly 2025 Macro Moves & Entry and Exit Point Strategies - Newser
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Gap DownHere's Why - MarketBeat
NAMS: PREVAIL CVOT remains on track for 2026, with regulatory and commercial momentum building - TradingView
JPMorgan Chase & Co. Increases Stock Position in NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
How NewAmsterdam Pharma Company N.V. (KH6) stock trades after earningsWeekly Trade Analysis & Consistent Profit Trade Alerts - Newser
Transcript : NewAmsterdam Pharma Company N.V. Presents at Citi Annual Global Healthcare Conference 2025, Dec-03-2025 03 - marketscreener.com
Is NewAmsterdam Pharma Company N.V. (KH6) stock a defensive play amid uncertaintyEarnings Summary Report & Reliable Intraday Trade Alerts - Newser
Will NewAmsterdam Pharma Company N.V. stock benefit from commodity pricesGap Down & Smart Money Movement Alerts - Newser
Will NewAmsterdam Pharma Company N.V. (KH6) stock announce special dividendWeekly Earnings Recap & Technical Entry and Exit Alerts - Newser
Is NewAmsterdam Pharma Company N.V. Equity Warrant stock a dividend growth opportunity2025 Risk Factors & AI Forecasted Entry and Exit Points - Newser
Why NewAmsterdam Pharma Company N.V. (KH6) stock signals breakout potential2025 Stock Rankings & Low Drawdown Momentum Ideas - Newser
Franklin Resources Inc. Purchases 78,300 Shares of NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
(NAMS) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Can NewAmsterdam Pharma Company N.V. Equity Warrant stock outperform in 2025 bull marketPortfolio Gains Report & Technical Buy Zone Confirmation - BỘ NỘI VỤ
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December - Sahm
NewAmsterdam Pharma (NASDAQ:NAMS) Sets New 12-Month HighHere's Why - MarketBeat
NewAmsterdam Pharma stock hits all-time high at 41.56 USD - Investing.com India
NewAmsterdam Pharma stock hits all-time high at 41.56 USD By Investing.com - Investing.com Australia
NewAmsterdam (Nasdaq: NAMS) to host investor fireside chats at Evercore, Citi, Piper - Stock Titan
Handelsbanken Fonder AB Boosts Holdings in NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
Discipline and Rules-Based Execution in NAMSW Response - news.stocktradersdaily.com
What drives NewAmsterdam Pharma Company NV KH6 stock priceDebt-to-Equity Ratio Analysis & Get Ahead with Our Profit-Packed Picks - earlytimes.in
Is NewAmsterdam Pharma Company N.V. Equity Warrant stock a top pick in earnings seasonSwing Trade & Safe Investment Capital Preservation Plans - newser.com
Can a trend reversal in NewAmsterdam Pharma Company N.V. Equity Warrant lead to recovery - newser.com
Technical analysis overview for NewAmsterdam Pharma Company N.V. Equity Warrant stockMarket Movers & Risk Controlled Stock Alerts - newser.com
Is NewAmsterdam Pharma Company N.V. stock a good choice for value investorsQuarterly Risk Review & Weekly Market Pulse Alerts - newser.com
Will NewAmsterdam Pharma Company N.V. stock maintain dividend yield - newser.com
Is NewAmsterdam Pharma Company N.V. (KH6) stock a fit for income portfoliosOil Prices & Long-Term Growth Stock Strategies - newser.com
How NewAmsterdam Pharma Company N.V. stock performs in high volatility marketsPortfolio Gains Report & Safe Entry Zone Identification - newser.com
What does recent volatility data suggest for NewAmsterdam Pharma Company N.V. Equity WarrantPortfolio Growth Summary & Technical Buy Zone Confirmation - newser.com
How NewAmsterdam Pharma Company N.V. (KH6) stock compares with tech leaders2025 Momentum Check & Risk Adjusted Swing Trade Ideas - newser.com
Visual analytics tools that track NewAmsterdam Pharma Company N.V. Equity Warrant performanceIndex Update & Weekly High Momentum Picks - newser.com
How NewAmsterdam Pharma Company N.V. Equity Warrant stock performs in stagflation2025 Biggest Moves & AI Forecast for Swing Trade Picks - newser.com
Will NewAmsterdam Pharma Company N.V. Equity Warrant stock recover faster than marketJuly 2025 Patterns & Weekly Top Gainers Trade List - newser.com
(NAMS) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Can NewAmsterdam Pharma Company N.V. Equity Warrant stock withstand economic slowdownJuly 2025 Action & Precise Swing Trade Entry Alerts - newser.com
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Will NewAmsterdam Pharma Company N.V. Equity Warrant stock maintain momentum in 2025 - newser.com
Published on: 2025-11-16 17:37:14 - newser.com
Advanced analytics toolkit walkthrough for NewAmsterdam Pharma Company N.V. Equity WarrantMarket Volume Report & Low Drawdown Momentum Trade Ideas - newser.com
Newamsterdam Pharma Company N V Stock (NAMSW) Financials Data
There is no financial data for Newamsterdam Pharma Company N V (NAMSW). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.44%
0.91%
Cap:
|
Volume (24h):